IMR Press / FBL / Volume 19 / Issue 3 / DOI: 10.2741/4217

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with Frontiers in Bioscience.

Role of melatonin supplementation in neurodegenerative disorders
Show Less
1 IRCCS Centro Neurolesi, Bonino-Pulejo, Messina, Italy
2 Department of Biological and Environmental Sciences, University of Messina, Messina, Italy
3 Dermatology Unit, AORNAS, Garibaldi, Hospital, Catania, Italy
4 Department of Biomedical Sciences, University of Catania, Italy
5 Department of Social Territorial Medicine, Section of Dermatology, University of Messina, Italy
Academic Editor:Fabio Galvano
Front. Biosci. (Landmark Ed) 2014, 19(3), 429–446;
Published: 1 January 2014
(This article belongs to the Special Issue Dietary approaches to prevent chronic-degenerative diseases)

Neurodegenerative diseases are chronic and progressive disorders characterized by selective destruction of neurons in motor, sensory and cognitive systems. Despite their different origin, free radicals accumulation and consequent tissue damage are importantly concerned for the majority of them. In recent years, research on melatonin revealed a potent activity of this hormone against oxidative and nitrosative stress-induced damage within the nervous system. Indeed, melatonin turned out to be more effective than other naturally occurring antioxidants, suggesting its beneficial effects in a number of diseases where oxygen radical-mediated tissue damage is involved. With specific reference to the brain, the considerable amount of evidence accumulated from studies on various neurodegeneration models and recent clinical reports support the use of melatonin for the preventive treatment of major neurodegenerative disorders. This review summarizes the literature on the protective effects of melatonin on Alzheimer disease, Parkinson disease, Huntington's disease and Amyotrophic Lateral Sclerosis. Additional studies are required to test the clinical efficacy of melatonin supplementation in such disorders, and to identify the specific therapeutic concentrations needed.

Dietary supplementation
Neurodegenerative disorders
Back to top